TRAF1 Antikörper (AA 73-219) (CF®647)

Produktnummer ABIN7660891

Dieses Maus Monoklonal-Antikörper erkennt spezifisch TRAF1 in IHC und IHC (fp). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für TRAF1 Antikörper (AA 73-219) (CF®647) (ABIN7660891)

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TRAF1 Antikörper ist konjugiert mit CF®647

Applikation: Immunohistochemistry (IHC), Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))

Klon: TRAF1-3298

Produktdetails anti-TRAF1 Antikörper (CF®647)

Bindungsspezifität: AA 73-219

Verwendungszweck: TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker)(TRAF1/3298), CF647 conjugate

Produktmerkmale: This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Immunogen: Recombinant fragment of human TRAF1 protein (around aa 73-219)

Isotyp: IgG2b, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Positive Control: HeLa or 293T cells. Hodgkin s Lymphoma (IHC).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.1 % BSA, 0.05 % azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from light

Lagerung: 4 °C

Informationen zur Lagerung:

Stable at room temperature or 37°C for 7 days.

Protect from light

Store at 2 to 8°C. Protect fluorescent conjugates from light

Haltbarkeit: 24 months

Details zu TRAF1

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Andere Bezeichnung: TRAF1

Hintergrund:

Synonyms: EBI6, EBV induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1, TRAF1

Gene Symbol: TRAF1

Molekulargewicht: 52 kDa

Gen-ID: 7185

UniProt: Q13077

Pathways: NF-kappaB Signalweg, Apoptose, Cell-Cell Junction Organization, Asymmetric Protein Localization